



## Invited review

# Immunomodulatory effects of fluoxetine: A new potential pharmacological action for a classic antidepressant drug?



María Emilia Di Rosso<sup>a</sup>, María Laura Palumbo<sup>b</sup>, Ana María Genaro<sup>a,c,\*</sup>

<sup>a</sup> Instituto de Investigaciones Biomédicas (BIOMED), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)—Universidad Católica Argentina (UCA), Av. Alicia Moreau de Justo 1600, Piso 3, 1107 Buenos Aires, Argentina

<sup>b</sup> Centro de Investigaciones y Transferencia del Noroeste de la Provincia de Buenos Aires (CIT NOBA), CONICET—Universidad Nacional del Noroeste de la Provincia de Buenos Aires (UNNOBA), Monteagudo 2772, Pergamino, 2700 Buenos Aires, Argentina

<sup>c</sup> Departamento de Farmacología, Facultad de Medicina, Universidad de Buenos Aires (UBA), Paraguay 2155, Piso 15, 1121 Buenos Aires, Argentina

## ARTICLE INFO

## Article history:

Received 27 October 2015

Received in revised form

24 November 2015

Accepted 25 November 2015

Available online 28 November 2015

## Keywords:

Antidepressant

Fluoxetine

Serotonin

Immune system

Immunomodulation

## ABSTRACT

Selective serotonin reuptake inhibitors are frequently used antidepressants. In particular, fluoxetine is usually chosen for the treatment of the symptoms of depression, obsessive–compulsive, panic attack and *bulimia nervosa*. Antidepressant therapy has been associated with immune dysfunction. However, there is contradictory evidence about the effect of fluoxetine on the immune system. Experimental findings indicate that lymphocytes express the serotonin transporter. Moreover it has been shown that fluoxetine is able to modulate the immune function through a serotonin-dependent pathway and through a novel independent mechanism. In addition, several studies have shown that fluoxetine can alter tumor cell viability. Thus, it was recently demonstrated *in vivo* that chronic fluoxetine treatment inhibits tumor growth by increasing antitumor T-cell activity.

Here we briefly review some of the literature referring to how fluoxetine is able to modify, for better or worse, the functionality of the immune system. These results of our analysis point to the relevance of the novel pharmacological action of this drug as an immunomodulator helping to treat several pathologies in which immune deficiency and/or deregulation is present.

© 2015 Elsevier Ltd. All rights reserved.

## Contents

1. Introduction .....	101
2. Role of serotonin as a regulator of immune response .....	102
3. Alteration of serotonin homeostasis in disease .....	103
4. Fluoxetine action on immune system .....	103
5. Concluding Remarks .....	105
Acknowledgments .....	105
References .....	105

## 1. Introduction

Serotonin [5-hydroxytryptamine (5-HT)] and catecholamines are primitive biogenic amines essential to the regulation of central

processes, like food and sexual appetite, mood, sleep, body temperature and breathing. Their bioavailability is exquisitely regulated through diverse mechanisms, such as vesicular sequestration mediated by selective transporters. In addition, these neurotransmitters and the corresponding transporter proteins are found in peripheral cells, mainly those of the immune–inflammatory axis. Also it has been described that they are able to modulate immune cell activity in an autocrine manner. These transporters have been used widely as pharmacological targets for the treatment of mood and anxiety-related disorders. Specifically, selective 5-HT reuptake inhibitors (SSRIs) have been demonstrated to be very efficient, safe and toler-

\* Corresponding author at: Instituto de Investigaciones Biomédicas (BIOMED), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET)—Universidad Católica Argentina (UCA), Av. Alicia Moreau de Justo 1600, Piso 3, 1107 Buenos Aires, Argentina.

E-mail address: [amgenaro@yahoo.com.ar](mailto:amgenaro@yahoo.com.ar) (A.M. Genaro).

able. In particular, fluoxetine is usually chosen for the treatment of the symptoms of depression, obsessive–compulsive disorder, panic attacks and *bulimia nervosa*. However, antidepressant therapy has been associated with alterations of the immune function.

Here we concisely review the literature pertaining to how fluoxetine is able to modify – for good or ill – the functionality of the immune system. Firstly, we describe the evidence on the presence and the role of 5-HT and of the transporters within the immune system. Secondly, we mention the findings about the alteration of 5-HT homeostasis in affective disorders and other pathologies such as cancer. Thirdly, the effect of fluoxetine on the immune response in both healthy subjects and in sickness conditions will be depicted.

## 2. Role of serotonin as a regulator of immune response

During the last twenty years experimental findings have indicated reciprocal communication between the immune and nervous systems, where 5-HT has been proven to have important modulatory effects [1–5]. Enterochromaffin cells of the gastrointestinal tract are the main producers of 5-HT. These cells release 5-HT, which is taken up by platelets that then act as “mobile storage units”. The rapid release of platelet 5-HT is induced by inflammatory stimuli, such as C5a, platelet activating factor and IgE-containing immune complexes. Thus, at sites of inflammation, lymphocytes can be exposed to large amounts of platelet-derived 5-HT, reaching near 1 mM in the local milieu [3]. In addition, immune cells contain and synthesize 5-HT [6–9]. The content may be different between diverse subtypes of cells, in lymphocytes and monocytes, and even in subpopulations of T lymphocytes. These differences could indicate particular roles of 5-HT as an immunomodulatory factor acting as an autocrine transmitter. For example, dendritic cells are able to uptake and store 5-HT, and then release it by exocytosis, inducing proliferation and differentiation of naive T cells [10]. Therefore autocrine and paracrine interplays might take place among lymphocytes.

The neuroimmune axis constitutes one more source of 5-HT for lymphocytes. It is known that lymphoid organs are extensively innervated by the autonomic nervous system. It has been proposed that nerve fibers in close contact with lymphoid tissues might take up 5-HT and then release it on following stimulation of the nerves [3]. Several studies have shown that 5-HT is able to regulate numerous immune responses by increasing of mitogen-stimulated lymphocyte proliferation, promoting natural killer (NK) cell activation and macrophage/dendritic accessory function as well as contributing to the initiation of the delayed-type hypersensitivity response [3,11,12].

Within the immune system, 5-HT can be transformed through catabolic pathways in melatonin, a cyclooxygenase inhibitor called formyl-*N*-acetyl-5-methoxykynurenamine, formyl-5-hydroxykynurenamine, 5-hydroxyindoleacetic acid and *N*-methylserotonin. However, it is not thoroughly understood the extent by which these metabolites generated during catabolism may affect the immune system [for a review see Ref. [13]].

Membrane receptors for 5-HT are, at present, grouped into 7 families, known as 5-HT1 to 5-HT7 [13]. In mammalian, 14 different 5-HT receptor subtypes have been found using molecular biological techniques. The 5-HT1 subgroup includes at least five subtypes: 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E and 5-HT1F. The 5-HT2 consists of three subtypes: 5-HT2A, 5-HT2B and 5-HT2C. For 5-HT5 two related receptor were identified: 5-HT5A and 5-HT5B. Excluding the 5-HT3 receptor that is a cation channel, all subtypes are G-protein-coupled receptors. 5-HT1, 5-HT4, 5-HT6, 5-HT7 sub-

groups are linked to adenylate cyclase and 5-HT2 to phospholipase C. The second messenger system coupled to the 5-HT5 receptors has not been identified yet; however, evidence exists indicating the functional coupling of the rat 5-HT5A receptor subtype to adenylate cyclase [14,15].

The presence of 5-HT receptors in the immune system, such as 5-HT1, 5-HT2, 5-HT3 and 5-HT7, has mostly been studied by pharmacological methods [3]. Stefulj et al. [16] investigated the mRNA expression of 5-HT receptors in rat lymphoid tissue cells and in mitogen-stimulated spleen cells by RT-PCR methods. The authors found that 5-HT1B, 5-HT1F, 5-HT2A, 5-HT2B, 5-HT6 and 5-HT7 receptor mRNAs are expressed in *ex vivo* isolated thymus, spleen, and peripheral blood lymphocytes. Mitogen-stimulated cells also expressed 5-HT3 receptor subtype mRNA. However, mRNA corresponding to 5-HT1A, 5-HT1D, 5-HT2C, 5-HT4, 5-HT5A and 5-HT5B subtypes were undetected in the examined lymphoid populations [16]. Other authors, however found 5-HT1A receptor to be expressed in lymphocytes, where it is involved in the promotion of T-cell proliferation, a property conserved between mammals and fish [8,9]. In addition 5-HT1A receptor is expressed in B lymphocytes and, as with T cells, both mRNA and protein for this receptor are up-regulated by NF- $\kappa$ B-dependent mechanisms [17]. Moreover, 5-HT1A receptor seems to participate in the 5-HT-augmentation of rodent splenic B cells mitogenic responses induced by lipopolysaccharide and dextran sulfate [18].

Antagonism of 5-HT1B/D receptors inhibits proliferation of human and murine T cells [19] and agonism of 5-HT1A receptors increases proliferation of rat [20], mouse [21] and human [22] lymphocytes, indicating a crucial role of 5-HT as an immunomodulator [23]. Also, the expression of 5-HTR2A in PBMC has been investigated and linked to the regulation of tumor necrosis factor (TNF)- $\alpha$  and interleukin (IL)-1 $\beta$  secretion [24]. Furthermore, it was demonstrated that 5-HT3, 5-HT4 and 5-HT7 subtypes regulate the release of IL-1 $\beta$ , IL-6, IL-12, IL-8 and TNF- $\alpha$  in monocytes and dendritic cells [12,25,26]. It was reported that 5-HT3A is expressed in naive and activated B-lymphocytes [27], T lymphocytes, and human monocytes [28]. Inhibition of the 5-HT3 receptors with antagonists, such as ondasetron and tropisetrol, disrupts TNF- $\alpha$  and IL-1 $\beta$  production, suggesting that these receptors may activate the p38/MAPK pathway [29,30]. Besides, 5-HT regulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells [12]. Table 1 shows the different receptor subtypes and the effect of 5-HT in different cell types.

High affinity uptake of 5-HT and its inhibition by SSRIs in peripheral-blood lymphocytes has been described [31]. In addition, the expression of the 5-HT transporter (SERT) has been demonstrated by specific saturable binding of the labeled SSRI paroxetine on lymphocytes [32]. It is important to note that the capacity to accumulate 5-HT seems to be evolutionarily conserved among lymphocytes suggesting that lymphoid SERT has a relevant role, if not a crucial function, within the periphery [6,33].

Cytokine modulation of SERT mRNA expression *in vitro* has been reported [34–37]. Furthermore, TNF- $\alpha$ , IL-6, IL-10, IFN- $\gamma$  production requires intracellular lymphocyte 5-HT, but this production may be suppressed by an increase in extracellular 5-HT concentration [38]. These observations suggest that SERT could be able to regulate the production of cytokines.

Experimental evidence shows that SERT does not act just as a transport protein but also as a substrate-dependent signal transducer [39]. In addition, SERT-delivered 5-HT has been probed to impact signal transduction directly by a novel mechanism, the “serotonylation” of small GTPases [40,41]. Thus, SERT appears equipped to modify cell’s functional behavior in potentially diverse ways [15].

**Table 1**  
5-HT receptor subtype and serotonin action in immune cells.

Immune cell type	5-HT receptor subtype	5-HT effect
T-cell	5-HT1A, 5-HT1B, 5HT2A, 5HT3, 5HT7 <sup>13–15</sup>	–Induction of Na <sup>+</sup> influx <sup>22</sup> –Induction of IL-16 secretion from CD8 <sup>+</sup> T cell <sup>22</sup> –Enhancement of proliferation <sup>22</sup> –Potentiation of T-cell activation <sup>22</sup> –Increase of IL-2 and IFN- $\gamma$ production <sup>22</sup>
B-cell	5-HT1A <sup>17</sup>	–Increase of proliferation <sup>17</sup>
Dendritic cell	5-HT1B, 5-HT2, 5-HT3, 5-HT4, 5-HT7 <sup>12</sup>	–Induction of oriented migration in immature DC <sup>12</sup> –Induction of Th2-cell polarization capacity of mature DC <sup>12</sup> –Inhibition of CXCL10 production in mature DC <sup>12</sup> –Stimulation of CCL22 production in mature and immature DC <sup>12</sup> –Stimulation of IL-1 $\beta$ , IL-6 and IL-8 in mature DC <sup>12,26</sup> –Inhibition of IL-12, TNF- $\alpha$ in mature DC <sup>26</sup> –Stimulation of IL-10 in LPS-stimulated mature DC <sup>12</sup> –Inhibition of IL-12p70 in LPS-stimulated mature DC <sup>12</sup>
Macrophage	5-HT1E, 5-HT2A, 5-HT3, 5-HT4, 5-HT7 <sup>23</sup>	–Stimulation of IL-1 $\beta$ , IL-6, IL-8 and IL-12 <sup>25</sup> –Inhibition of TNF- $\alpha$ release <sup>25</sup>

Abbreviations: DC: dendritic cells; CXCL10: chemokine 10; CCL22: chemokine 22; LPS: lipopolysaccharide.

### 3. Alteration of serotonin homeostasis in disease

Reports indicating alterations on 5-HT homeostasis in immune system are referred especially to psychiatric disorders, such as the major depressive disorder; immune dysfunction and malignant immune cells, like Burkitt lymphoma.

The major depressive disorder is defined as a pervasive and persistent low mood with a multi-factor cause. It has long been considered that dysfunction of the central serotonergic system is involved in the pathogenesis of this disorder. Several studies have shown that 5-HT manipulations alter subjective emotional state [42]. Kambeitz and Howes [43] performed a meta-analysis of *in vivo* and *post mortem* findings and conclude that SERT availability is diminished in crucial regions of the limbic system in depressed patients. However, it was reported that there are no variation in the plasma levels of circulating 5-HT and their metabolite 5-hydroxyindoleacetic acid (5-HIAA) [6,44]. Nevertheless, in major depression patients a reduction was found in lymphoid SERT that was increased after fluoxetine [6] or mirtazapine treatment [44]. In addition, a decrease of the SERT mRNA was described in these patients [7]. SERT protein expression in leukocytes has, however, been found in other studies to be increased in depressive patients and reverted by antidepressant administration [45]. These different results may be linked to the type of cell preparation utilized or the type of patients evaluated in each study. These findings support the significant action of SERT on different circulating cells playing an important role for the maintenance of serotonergic homeostasis such as it happens in the brain.

Changes in lymphocyte proliferation have been described in depression. Thus, it has been reported a lower mitogen-induced T cell proliferation in depressed patients [46–48]. However, the probability of a basal immune activation in these patients that in turn promote an autoimmune reaction cannot be discarded. In fact, in depression, it was reported an increased basal lymphocyte proliferation, an over-reactivity of 5-HT1A receptors [48] and a reduction of lymphocyte cAMP [49]. Moreover, other immune variations were evidenced, such as leukocytosis with lymphopenia and increased CD4<sup>+</sup>/CD8<sup>+</sup> ratio [50]. Besides, some studies have shown an increase in the CD3<sup>+</sup>/CD8<sup>+</sup> ratio without modification in CD3<sup>+</sup>CD4<sup>+</sup> lymphocytes and a higher percentage of NK cells in major depression [51]. Finally, Fazzino et al. [52] found a decreased number of SERT in CD8<sup>+</sup> lymphocytes without changes in CD4<sup>+</sup>/CD8<sup>+</sup> relation in major depression. The presence of SERT in CD4<sup>+</sup> and CD8<sup>+</sup> cells may be indicative of the existence of differential serotonergic system regulation of cell activity in lymphocyte subpopulations.

Immune responses to viruses, bacteria, fungi, and parasites require 5-HT. Human immunodeficiency virus (HIV) infection is a primary model for the study of the action of 5-HT during infection. Numerous studies encourage a role of 5-HT in T-cell function of HIV-seropositive individuals. 5-HT induces a decrease of intracellular cAMP levels in lymphocytes and an increase of proliferative responses mediated by IL-2 production through 5-HT1A receptors [53]. In addition, 5-HT decreases the expression of the HIV co-receptor CCR5 on infected macrophages and reduces proviral synthesis by 50% [54].

The role of the serotonergic system in cancer patients is still under investigation. Increased levels of systemic 5-HT appears to correlate with advanced stages of breast cancer [55]. Serafeim et al. [56] showed in established Burkitt lymphoma (BL) cell lines that 5-HT plays an important role in driving programmed cell death. Despite Burkitt lymphoma being a very aggressive tumor, it shows a propensity to apoptosis, as indicated by its classical starry sky histology. The authors described that 5-HT induced a considerable suppression of DNA synthesis in parallel with an important apoptosis in BL cells culture. These effects were anteceded by early caspase activation and mitochondrial membrane potential disruption. However, 5-HT receptor antagonists (*i.e.*, granisetron, methysergide, SDZ205-557) were not able to inhibit 5-HT-driven apoptosis, while fluoxetine, paroxetine, and citalopram extensively blocked the monoamine actions. Nevertheless, SSRIs directly signal for apoptosis in these cells [57]. The presence of SERT, as well as the active uptake of 5-HT indicated by transport assays in BL cells, suggest that 5-HT is able to drive apoptosis by an active transport mechanism.

### 4. Fluoxetine action on immune system

Experimental findings suggest that antidepressants can modulate the proliferation of immune cells. However, there is conflicting evidence about the action of fluoxetine on the immune system. Pellegrino and Bayer [58,59] described a reduced mitogen-induced T lymphocyte proliferation after acute, but not chronic fluoxetine therapy. In addition, the subchronic administration of fluoxetine in depressed patients regularized the initially increased plasma concentrations of pro-inflammatory cytokines IL-6 [60] and IL-1 $\beta$  [61]. Repeated treatment with fluoxetine and tricyclic antidepressants (TCAs) might suppress the acute phase response in major depression [62]. On the contrary, we described that after 4 weeks treatment with fluoxetine in normal mice, an augmentation of T cell mediated immunity occurs. Thus, an increase of T cell proliferation

**Table 2**  
Immunomodulatory effect of fluoxetine in pathology.

Pathological situation	Immune alteration	Fluoxetine effect
Inflammation	–Increase of INF- $\gamma$ and TNF- $\alpha$	–Decrease TNF- $\alpha$ and INF- $\gamma$ <sup>73,74</sup> –Increase of IL-10 <sup>72,75</sup>
Stress	–Decrease of phagocytosis –Decrease of T cell response –Decreased production of TNF- $\alpha$ , and INF- $\gamma$	–Restoration of phagocytosis <sup>68</sup> –Restoration of T cell response <sup>65–67</sup> –Enhance of TNF- $\alpha$ and INF- $\gamma$ production <sup>63</sup>
Depressive disorder	–Elevated basal and stimulated proliferation –High IL-6 levels and IL-1 $\beta$	–Normalization of both basal and stimulated proliferation <sup>52</sup> –Reduction of IL-6 <sup>60</sup> and IL-1 $\beta$ <sup>61</sup>

with no changes on CD4+/CD8+ ratio as well as an enhanced INF- $\gamma$  and TNF- $\alpha$  cytokines production was observed [63]. Experiments carried out with athymic mice – lacking of T lymphocytes – indicated that fluoxetine effects are selective for T cells, not found in other lymphocyte subpopulations [63]. On the other hand, Fazzino et al. [64] found that chronic administration of fluoxetine in normal rats induces a significant reduction of CD4+/CD8+ ratio and an increase of IL-4/IL-2 ratio. It is important to note that the antidepressant route of administration influences the effects observed. For instance, Fazzino et al. [64] administered fluoxetine intraperitoneally and our group [63] orally. It is probable that intraperitoneal injection represents an extra stressor that leads to an opposite effect.

Fluoxetine was shown to revert the stress-induced suppression on T lymphocyte population [65–67] and activity of phagocytosis [68] without affecting them in control mice. In addition, chronic restraint stress provokes a reduction of the total number of T CD4+ cells affecting T helper immunity in BALB/c mice. Nevertheless, according to our observations, fluoxetine increases T cell reactivity with no changes in the total number of T lymphocytes. This differential effect could be indicating that fluoxetine exerts this modulatory action on T helper immunity through compensatory and/or specific mechanisms [69]. Thus, it has been proposed that fluoxetine can act by indirect effects through the activation of central 5-HT<sub>2</sub> receptors [65], but that it may also mediate a direct regulation of peripheral cells [63,69,70]. In fact, *in vitro* results indicate that fluoxetine is able to modulate immune functions. It was shown that fluoxetine suppresses *in vitro* mitogen induced rat T- and B-lymphocyte proliferation in a dose-dependent manner [71]. Fazzino et al. [52] reported that elevated basal proliferation observed in patients with depression, as mentioned above, was reduced efficiently in the presence of fluoxetine. Besides, incubation of mitogen-stimulated human immune cells with fluoxetine *in vitro*, significantly reduces the production of the pro-inflammatory cytokines TNF- $\alpha$  and INF- $\gamma$ , and the INF- $\gamma$ /IL-10 production ratio, with [72] or without [73] significant increase of the anti-inflammatory cytokine IL-10. Moreover, desipramine and fluoxetine were able to suppress lymphocyte proliferation [71] and to decrease the inflammatory reaction and mortality in rat and murine models [74]. In addition, Kubera et al. [75] showed that both fluoxetine and desipramine significantly ameliorate the contact hypersensitivity induced by a topical application of hapten 2,4-dinitrofluorobenzene (DNFB). This effect is mediated by the suppression of the T cytotoxic-cell-mediated antigen-specific type of skin inflammation by antidepressant drugs. These findings suggest that these drugs may be beneficial therapeutic tools in the treatment of contact allergy. Table 2 reports the available information on the immunomodulatory effect of fluoxetine in pathological situations in which immune alterations play a role.

It is probable that the effect of fluoxetine on T-cell activity is related to the degree of lymphocyte activation. We found [69,70] that when lymphocytes were stimulated with optimal Concanavalin A (Con A) concentration fluoxetine promotes an increase of intracellular Ca<sup>2+</sup> levels that in turn induces proteolysis of protein

kinase C (PKC) increasing cAMP levels, so impairing lymphocyte proliferation. However, when suboptimal Con A concentration was utilized, fluoxetine increased PKC translocation, without affecting cAMP levels, leading to T-cell proliferation. These results suggest that fluoxetine has a dual activity on T-cell proliferation through Ca<sup>2+</sup> mobilization that influences PKC and protein kinase A pathways [69,70]. Accordingly, we reported a similar dual effect of fluoxetine on B-cell receptor (BCR)-driven murine B-cell proliferation [76]. In addition, Frank et al. showed that *in vitro* exposure of mononuclear cells to fluoxetine and paroxetine directly increase NK-cell activity [77].

Blockade of SERT may be followed by an increment in 5-HT concentration close the lymphocytes, modulating proliferation through specific receptors. To evaluate the role of 5-HT in the effects of fluoxetine on T-cell activity we determined the mitogen-induced proliferation in the presence of 5-HT or fluoxetine alone and in combination with fluoxetine. We [63] found that 5-HT and fluoxetine have similar effects; both were capable of stimulating the proliferation induced by suboptimal Con A and of inhibiting the optimal one. However, for 5-HT, these effects were directly related to the concentration used. On the contrary, the stimulatory effect of fluoxetine was inversely linked to the concentration used, whereas the inhibitory effect was directly related to fluoxetine concentrations. When combinations of 5-HT and fluoxetine were used, 5-HT was able to decrease the inhibitory effect of fluoxetine at optimal Con A-induced proliferation and to increase the stimulatory effect of fluoxetine on suboptimal Con A stimulated proliferation. These results point out that the modulatory effects of fluoxetine are partially independent of its capacity to increase 5-HT extracellular levels. This mechanism might introduce the action of fluoxetine through a novel receptor or new intracellular pathway coupled to 5-HT transport [63,67].

The evidence summarized above suggests that SERT cannot only remove the monoamine from the extracellular space, but also, under particular conditions pump 5-HT out of cells. Moreover, it is now perceived that intracellular 5-HT is not simply passive since the “serotonylation” of small GTPases, like Rho and Rac, induce their degradation directly impacting on signal transduction [15].

It is important to note that fluoxetine *per se* has an immunomodulatory effect in normal animals. We demonstrated that fluoxetine alone increases mitogen-induced T cell proliferation and IL-2, INF- $\gamma$  and TNF- $\alpha$  expression over control levels [63]. Moreover, we found that fluoxetine was able to inhibit tumor growth, retard its appearance, and prolong survival of mice. These effects were maximal in animals receiving continuously fluoxetine. However, if fluoxetine is administered only before or after tumor injection, a decrease in tumor progression and an increase in survival were also observed. An outstanding finding is the fact that the survival was increased when fluoxetine was administered after tumor injection, suggesting a potential pharmacological beneficial effect of fluoxetine on cancer therapy [63].

A relevant question is thus which dose of fluoxetine is to be used. It was reported that the oral intake of 10 and 25 mg/kg/day of fluoxetine in BALB/c mice yield a plasma concentration near




Fig. 1. Hypothetical pathways for fluoxetine immunomodulatory effects.

170–1780 ng/ml, corresponding to  $5 \times 10^{-7}$  M to  $5 \times 10^{-6}$  M [78]. In addition the range of plasma levels reported in patients consuming 20–80 mg/day Prozac is near 100–700 ng/ml [79], equivalent to a fluoxetine concentration of  $2 \times 10^{-7}$  M to  $3 \times 10^{-6}$  M. Using these doses we demonstrated that fluoxetine improves the reduced T cell proliferation found in stressed mice both *in vivo* and *in vitro* [67]. These results emphasize that when the direct effects are analyzed by *in vitro* approaches, the antidepressant concentration used is crucial since the cytotoxic/apoptotic phenomena could be just due to high doses of these drugs, but not necessary an effect occurring *in vivo*.

## 5. Concluding Remarks

Based on the above described actions of fluoxetine on immune responses, it has been proposed that serotonergic and dopaminergic pathways offer an attractive target to treat human immune system disorders.

Despite some conflicting experimental findings, in general it appears that fluoxetine is able to modulate the immune response. Thus, when basal immune function is high, fluoxetine administration reduces lymphocyte activity. On the contrary, when immune function is deficient, fluoxetine administration improves it.

Fluoxetine can exert its effect by direct and indirect mechanisms. Indirect mechanisms would be 5-HT-dependent or independent (Fig. 1). It is relevant to note that the concentration used for analyzing the direct action of fluoxetine *in vitro* is crucial taking into account that cytotoxic/apoptotic effects can be due to

the usage of high doses of this drug, not necessarily occurring at the concentration found when the drug is administered *in vivo*.

These results highlight the importance of the novel pharmacological action of this drug as an immunomodulator, helping to treat several pathologies that course with immune deficiency and/or deregulation.

Fluoxetine can exert immunomodulatory effects by its action on serotonergic neurons in the central nervous system regulating neuroendocrine signals. In addition, fluoxetine is also able to act directly on T lymphocytes modulating their proliferation in a dual manner depending on cellular activation. This mechanism could include: (a) the action through a novel receptor or a novel intracellular pathway coupled to 5-HT transport, (b) the increase of 5-HT in the lymphocyte milieu which in turn activates intracellular signals by binding to serotonergic receptors, and (c) the increase of intracellular 5-HT leading to “serotonylation” of small GTPases. The crosstalk of different events leads to the immunoregulatory effect in the presence of antigen or inflammatory stimulus.

## Acknowledgments

This work was supported by grants from CONICET and UBA. M.E.D is a research fellow from CONICET. M.L.P and A.M.G. are researchers from CONICET.

## References

- [1] J.C. Jackson, R.J. Cross, R.F. Walker, W.R. Markesbery, W.H. Brooks, Influence of serotonin on the immune response, *Immunology* 54 (1985) 505–512.

- [2] E.M. Sternberg, J. Trial, C.W. Parker, Effect of serotonin on murine macrophages: suppression of Ia expression by serotonin and its reversal by 5-HT<sub>2</sub> serotonergic receptor antagonists, *J. Immunol.* 137 (1986) 276–282.
- [3] R. Mossner, K.P. Lesch, Role of serotonin in the immune system and in neuroimmune interactions, *Brain Behav. Immun.* 12 (1998) 249–271.
- [4] T.C. Pellegrino, B.M. Bayer, Specific serotonin reuptake inhibitor-induced decreases in lymphocyte activity requires endogenous serotonin release, *Neuroimmunomodulation* 8 (2000) 179–187.
- [5] J.A. Moynihan, F.M. Santiago, Brain behavior and immunity: twenty years of T cells, *Brain Behav. Immun.* 21 (2007) 872–880.
- [6] M. Urbina, S. Pineda, L. Piñango, I. Carreira, L. Lima, [3H]Paroxetine binding to human peripheral lymphocyte membranes of patients with major depression before and after treatment with fluoxetine, *Int. J. Immunopharmacol.* 21 (1999) 631–646.
- [7] L. Lima, S. Mata, M. Urbina, Allelic isophorms and decrease of serotonin transporter mRNA in lymphocytes of major depression patients, *Neuroimmunomodulation* 12 (2005) 299–306.
- [8] G. Resler, R. Lavie, J. Campos, S. Mata, M. Urbina, A. García, R. Apitz, L. Lima, Effect of folic acid combined with fluoxetine in patients with major depression on plasma homocysteine and vitamin B12, and serotonin levels in lymphocytes, *Neuroimmunomodulation* 15 (2008) 145–152.
- [9] E. Pallinger, G. Csaba, Effect of serotonin-acting agents on the serotonin content of immune cells. A peculiar observation, *Cell Biochem. Funct.* 25 (2007) 581–583.
- [10] P.J. O'Connell, X. Wang, M. Leon-Ponte, C. Griffiths, S.C. Pingle, G.P. Ahern, A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells, *Blood* 107 (2006) 1010–1017.
- [11] J.E. Duffy-Whritenoura, J.T. Zelikoff, Relationship between serotonin and the immune system in a teleost model, *Brain Behav. Immun.* 22 (2008) 257–264.
- [12] T. Müller, T. Dürk, B. Blumenthal, M. Grimm, S. Cicko, E. Panther, S. Sorichter, Y. Herouy, F. Di Virgilio, D. Ferrari, J. Norgauer, M. Idzko, 5-Hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo, *PLoS One* 4 (2009) e6453.
- [13] R. Arreola, E. Becerril-Villanueva, C. Cruz-Fuentes, M.A. Velasco-Velázquez, M.E. Garcés-Alvarez, G. Hurtado-Alvarado, S. Quintero-Fabian, L. Pavón, Immunomodulatory effects mediated by serotonin, *J. Immunol. Res.* (2015) 354957 <http://dx.doi.org/10.1155/2015/>
- [14] M. Noda, H. Higashida, S. Aoki, K. Wada, Multiple signal transduction pathways mediated by 5-HT receptors, *Mol. Neurobiol.* 29 (2004) 31–40.
- [15] N.M. Barnes, J. Gordon, Harnessing serotonergic and dopaminergic pathways for lymphoma therapy: evidence and aspirations, *Semin. Cancer Biol.* 18 (2008) 218–225.
- [16] J. Stefulj, B. Jernej, L. Cicin-Sain, I. Rinner, K. Schauenstein, mRNA expression of serotonin receptors in cells of the immune tissues of the rat, *Brain Behav. Immun.* 14 (2000) 219–224.
- [17] M. Abdouh, J.M. Storrang, M. Riad, Y. Paquette, P.R. Albert, E. Drobetsky, E. Kouassi, Transcriptional mechanisms for induction of 5-HT<sub>1A</sub> receptor mRNA and protein in activated B and T lymphocytes, *J. Biol. Chem.* 276 (2001) 4382–4388.
- [18] K. Iken, S. Chheng, A. Fargin, A.C. Goulet, E. Kouassi, Serotonin up-regulates mitogen-stimulated B lymphocyte proliferation through 5-HT<sub>1A</sub> receptors, *Cell Immunol.* 163 (1995) 1–9.
- [19] J. Yin, R.H. Albert, A.P. Tretiakova, B.A. Jameson, 5-HT<sub>1B</sub> receptors play a prominent role in the proliferation of T-lymphocytes, *J. Neuroimmunol.* 181 (2006) 68–81.
- [20] T. Sempere, M. Urbina, L. Lima, 5-HT<sub>1A</sub> and beta-adrenergic receptors regulate proliferation of rat blood lymphocytes, *Neuroimmunomodulation* 11 (2004) 307–315.
- [21] M. Abdouh, P.R. Albert, E. Drobetsky, J.G. Filep, E. Kouassi, 5-HT<sub>1A</sub>-mediated promotion of mitogen-activated T and B cell survival and proliferation is associated with increased translocation of NF- $\kappa$ B to the nucleus, *Brain Behav. Immun.* 18 (2004) 24–34.
- [22] A. González, F. Fazzino, M. Castillo, S. Mata, L. Lima, Serotonin, 5-HT<sub>1A</sub> serotonin receptors and proliferation of lymphocytes in major depression patients, *Neuroimmunomodulation* 14 (2007) 8–15.
- [23] M. Levite, Neurotransmitters activate T-cells and elicit crucial functions via neurotransmitter receptors, *Curr. Opin. Pharmacol.* 8 (2008) 460–471.
- [24] I. Cloez-Tayarani, A.F. Petit-Bertron, H.D. Venters, J.M. Cavallion, Differential effect of serotonin on cytokine production in lipopolysaccharide-stimulated human peripheral blood mononuclear cells: involvement of 5-hydroxytryptamine 2A receptors, *Int. Immunol.* 15 (2003) 233–240.
- [25] T. Dürk, E. Panther, T. Müller, S. Sorichter, D. Ferrari, C. Pizzirani, F. Di Virgilio, D. Myrtek, J. Norgauer, M. Idzko, 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes, *Int. Immunol.* 17 (2005) 599–606.
- [26] M. Idzko, E. Panther, C. Stratz, T. Müller, H. Bayer, G. Zissel, T. Dürk, S. Sorichter, F. Di Virgilio, M. Geissler, B. Fiebich, Y. Herouy, P. Elsner, J. Norgauer, D. Ferrari, The serotonergic receptors of human dendritic cells: identification and coupling to cytokine release, *J. Immunol.* 172 (2004) 6011–6019.
- [27] A. Rinaldi, A.M. Chiaravalli, M. Mian, E. Zucca, M.G. Tibiletti, C. Capella, F. Berton, Serotonin receptor 3A expression in normal and neoplastic B cells, *Pathobiology* 77 (2010) 129–135.
- [28] B.L. Fiebich, R.S. Akundi, M. Seidel, V. Geyer, U. Haus, W. Müller, T. Stratz, E. Candelario-Jalil, Expression of 5-HT<sub>3A</sub> receptors in cells of the immune system, *Scand. J. Rheumatol. Suppl.* 119 (2004) 9–11.
- [29] B.L. Fiebich, R.S. Akundi, K. Lieb, E. Candelario-Jalil, D. Gmeiner, U. Haus, W. Müller, T. Stratz, E. Muñoz, Antiinflammatory effects of 5-HT<sub>3</sub> receptor antagonists in lipopolysaccharide stimulated primary human monocytes, *Scand. J. Rheumatol. Suppl.* 119 (2004) 28–32.
- [30] C. Stratz, H.S. Bhatia, R.S. Akundi, T. Nührenberg, D. Trenk, E. Muñoz, B.L. Fiebich, The anti-inflammatory effects of the 5-HT<sub>3</sub> receptor antagonist tropisetron are mediated by the inhibition of p38 MAPK activation in primary human monocytes, *Int. Immunopharmacol.* 13 (2012) 398–402.
- [31] B.A. Faraj, Z.L. Olkowski, R.T. Jackson, Expression of a high-affinity serotonin transporter in human lymphocytes, *Int. J. Immunopharmacol.* 16 (1994) 561–567.
- [32] D. Marazziti, A. Rossi, G. Giannaccini, S. Baroni, A. Lucacchini, G.B. Cassano, Presence and characterization of the serotonin transporter in human resting lymphocytes, *Neuropsychopharmacology* 19 (1998) 154–159.
- [33] F. Ferriere, N.A. Khan, J.P. Meyniel, P. Deschoux, Characterization of serotonin transport mechanisms in rainbow trout peripheral blood lymphocytes: role in PHA-induced lymphoproliferation, *Dev. Comp. Immunol.* 23 (1999) 37–50.
- [34] O. Morikawa, N. Sakai, H. Obara, N. Saito, Effects of interferon-alpha, interferon gamma and cAMP on the transcriptional regulation of the serotonin transporter, *Eur. J. Pharmacol.* 348 (1998) 317–324.
- [35] R. Mössner, A. Heils, G. Stöber, O. Okladnova, S. Daniel, K.P. Lesch, Enhancement of serotonin transporter function by tumor necrosis factor alpha but not by interleukin-6, *Neurochem. Int.* 33 (1998) 251–254.
- [36] R. Mössner, S. Daniel, A. Schmitt, D. Albert, K.P. Lesch, Modulation of serotonin transporter function by interleukin-4, *Life Sci.* 68 (2001) 873–880.
- [37] S. Ramamoorthy, J.D. Ramamoorthy, P. Prasad, G.K. Blat, V.B. Mahesh, Regulation of the human serotonin transporter by interleukin-1 beta, *Biochem. Biophys. Res. Commun.* 216 (1995) 560–567.
- [38] M. Kubera, V. Holan, R. Mathison, M. Maes, The effect of repeated amitriptyline and desimipramine administration on cytokine release in C57BL/6 mice, *Psychoneuroendocrinology* 25 (2000) 785–797.
- [39] J. Gordon, N.M. Barnes, Lymphocytes transport serotonin and dopamine: agony or ecstasy? *Trends Immunol.* 24 (2000) 438–443.
- [40] D.J. Walther, J.U. Peter, S. Winter, M. Hölte, N. Paulmann, M. Grohmann, J. Vowinkel, V. Alamo-Bethencourt, C.S. Wilhelm, G. Ahnert-Hilger, M. Bader, Serotonylation of small GTPases is a signal transduction pathway that triggers platelet alpha-granule release, *Cell* 115 (2003) 851–862.
- [41] C. Guilluy, M. Rolli-Derkinderen, P.L. Tharaux, G. Melino, P. Pacaud, G. Loirand, Transglutaminase-dependent RhoA activation and depletion by serotonin in vascular smooth muscle cells, *J. Biol. Chem.* 282 (2007) 2918–2928.
- [42] J.P. Roiser, J. Levy, S.J. Fromm, A.C. Nugent, S.L. Talagala, G. Hasler, F.A. Henn, B.J. Sahakian, W.C. Drevets, The effects of tryptophan depletion on neural responses to emotional words in remitted depression, *Biol. Psychiatry* 66 (2009) 441–450.
- [43] J.P. Kambeitz, O.D. Howes, The serotonin transporter in depression: meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression, *J. Affect. Disord.* 186 (2015) 358–366.
- [44] S. Peña, E. Baccichet, M. Urbina, I. Carreira, L. Lima, Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients, *Int. Immunopharmacol.* 5 (2005) 1069–1076.
- [45] J. Iga, S. Ueno, K. Yamauchi, I. Motoki, S. Tayoshi, K. Ohta, H. Song, K. Morita, K. Rokutan, T. Ohmori, Serotonin transporter mRNA expression in peripheral leukocytes of patients with major depression before and after treatment with paroxetine, *Neurosci. Lett.* 389 (2005) 12–16.
- [46] N. Müller, E. Hofschuster, M. Ackenheil, W. Mempel, R. Eckstein, Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis, *Prog. Neuropsychopharmacol. Biol. Psychiatry* 17 (1993) 713–730.
- [47] A. Anesi, D. Franciotta, E. Di Paolo, E. Zardini, G.V. Melzi d'Eril, F. Zerbi, PHA-stimulated cellular immune function and T-lymphocyte subsets in major depressive disorders, *Funct. Neurol.* 9 (1994) 17–22.
- [48] M.D. Zaharia, A.V. Ravindran, J. Griffiths, Z. Merali, H. Anisman, Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features, *J. Affect. Disord.* 58 (2000) 1–10.
- [49] C. Mizrahi, A. Stojanovic, M. Urbina, L. Lima, Differential cAMP levels and serotonin receptors in blood peripheral monocytes and lymphocytes of major depression patients, *Int. Immunopharmacol.* 4 (2004) 1125–1133.
- [50] E.P. Zorrilla, L. Luborsky, J.R. McKay, R. Rosenthal, A. Houlihan, A. Tax, R. McCorkie, D.A. Seligman, K. Schmidt, The relationship of depression and stressors to immunological assays: a meta-analytic review, *Brain Behav. Immun.* 15 (2001) 199–226.
- [51] L. Pavon, G. Sandoval-Lopez, M. Eugenia Hernández, F. Loria, I. Estrada, M. Pérez, J. Moreno, U. Avila, P. Leff, B. Antón, G. Heinze, The cytokine response in major depressive disorder patients before treatment, *J. Neuroimmunol.* 172 (2006) 156–165.
- [52] F. Fazzino, C. Montes, M. Urbina, I. Carreira, L. Lima, Serotonin transporter is differentially localized in subpopulations of lymphocytes of major depression patients. Effect of fluoxetine on proliferation, *J. Neuroimmunol.* 196 (2008) 173–180.
- [53] J. Eugen-Olsen, P. Afzelius, L. Andresen, J. Iversen, G. Kronborg, P. Aabech, J.O. Nielsen, B. Hofmann, Serotonin modulates immune function in T cells from HIV-seropositive subjects, *Clin. Immunol. Immunopathol.* 84 (1997) 115–121.

- [54] B. Manéglie, G.J. Guillemin, P. Clayette, C. Rogez-Kreuz, B.J. Brew, D. Dormont, C. Advenier, P. Therond, O. Spreux-Varoquau, Serotonin decreases HIV-1 replication in primary cultures of human macrophages through 5-HT<sub>1A</sub> receptors, *Br. J. Pharmacol.* 154 (2008) 174–182.
- [55] A. Frobe, L. Cicin-Sain, G. Jones, Ž. Soldič, J. Lukač, A. Bolanča, Z. Kusič, Plasma free serotonin is a marker for early detection of breast cancer recurrence, *Anticancer Res.* 34 (2014) 1167–1169.
- [56] A. Serafeim, G. Grafton, A. Chamba, C.D. Gregory, R.D. Blakely, N.G. Bowery, N.M. Barnes, J. Gordon, Hydroxytryptamine drives apoptosis in biopsyloma Burkitt lymphoma cells: reversal by selective serotonin reuptake inhibitors, *Blood* 99 (2002) 2545–2553.
- [57] A. Serafeim, M.J. Holder, G. Grafton, A. Chamba, M.T. Drayson, Q.T. Luong, C.M. Bunce, C.D. Gregory, N.M. Barnes, J. Gordon, Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells, *Blood* 101 (2003) 3212–3219.
- [58] T.C. Pellegrino, B.M. Bayer, Role of central 5-HT<sub>2</sub> receptors in fluoxetine-induced decreases in T lymphocyte activity, *Brain Behav. Immun.* 16 (2002) 87–103.
- [59] T.C. Pellegrino, B.M. Bayer, Modulation of immune cell function following fluoxetine administration in rats, *Pharmacol. Biochem. Behav.* 59 (1998) 151–157.
- [60] A. Szűzewska, J.K. Rybakowski, M. Laciak, A. Mackiewicz, M. Sobieska, K. Wiktorowicz, Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine, *Ann. N. Y. Acad. Sci.* 762 (1995) 474–476.
- [61] C. Song, U. Halbreich, C. Han, B.E. Leonard, H. Luo, Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment, *Pharmacopsychiatry* 42 (2009) 182–188.
- [62] M. Maes, J. Delange, R. Ranjan, H.Y. Meltzer, R. Desnyder, W. Cooremans, S. Scharpé, Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs, *Psychiatry Res.* 66 (1997) 1–11.
- [63] L.R. Frick, M.L. Palumbo, M.P. Zappia, M.A. Brocco, G.A. Cremaschi, A.M. Genaro, Inhibitory effect of fluoxetine on lymphoma growth through the modulation of antitumor T cell response by serotonin dependent and independent mechanisms, *Biochem. Pharmacol.* 75 (2008) 1817–1826.
- [64] F. Fazzino, M. Urbina, N. Cedeño, L. Lima, Fluoxetine treatment to rats modifies serotonin transporter and cAMP in lymphocytes, CD4<sup>+</sup> and CD8<sup>+</sup> subpopulations and interleukins 2 and 4, *Int. Immunopharmacol.* 9 (2009) 463–467.
- [65] M.J. Nunez, J. Balboa, E. Rodrigo, J. Brenlla, M. Gonzalez-Peteiro, M. Freire-Garabal, Effects of fluoxetine on cellular immune response in stressed mice, *Neurosci. Lett.* 396 (2006) 247–251.
- [66] V.A. Edgar, G.A. Cremaschi, L. Sterin-Borda, A.M. Genaro, Altered expression of autonomic neurotransmitter receptors and proliferative responses in lymphocytes from a chronic mild stress model of depression: effects of fluoxetine, *Brain Behav. Immun.* 16 (2002) 333–350.
- [67] L.R. Frick, M. Rapanelli, G.A. Cremaschi, A.M. Genaro, Fluoxetine directly counteracts the adverse effects of chronic stress on T cell immunity by compensatory and specific mechanisms, *Brain Behav. Immun.* 23 (2009) 36–40.
- [68] M. Freire-Garabal, M.J. Núñez, P. Riveiro, J. Balboa, P. López, B.G. Zamorano, E. Rodrigo, M. Rey-Méndez, Effects of fluoxetine on the activity of phagocytosis in stressed mice, *Life Sci.* 72 (2002) 173–183.
- [69] V.A. Edgar, L. Sterin-Borda, G.A. Cremaschi, A.M. Genaro, Role of protein kinase C and cAMP in fluoxetine effects on human T-cell proliferation, *Eur. J. Pharmacol.* 372 (1999) 65–73.
- [70] V.A. Edgar, A.M. Genaro, G. Cremaschi, L. Sterin-Borda, Fluoxetine action on murine T-lymphocyte proliferation: participation of PKC activation and calcium mobilisation, *Cell. Signal.* 10 (1998) 721–726.
- [71] M.B. Berkeley, S. Daussin, M.C. Hernández, B.M. Bayer, In vitro effect of cocaine, lidocaine and monoamine uptake inhibitors on lymphocyte proliferative responses, *Immunopharmacol. Immunotoxicol.* 16 (1994) 165–178.
- [72] M. Kubera, A.H. Lin, G. Kenis, E. Bosmans, D. van Bockstaele, M. Maes, Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio, *J. Clin. Psychopharmacol.* 21 (2001) 199–206.
- [73] M. Maes, G. Kenis, M. Kubera, M. De Baets, H. Steinbusch, E. Bosmans, The negative immunoregulatory effects of fluoxetine in relation to the cAMP-dependent PKA pathway, *Int. Immunopharmacol.* 5 (2005) 609–618.
- [74] C. Roumestan, A. Michel, F. Bichon, K. Portet, M. Detoc, C. Henriquet, D. Jaffuel, M. Mathieu, Antiinflammatory properties of desipramine and fluoxetine, *Respir. Res.* 3 (2007) 8–35.
- [75] M. Kubera, K. Curzytek, M. Majewska-Szczepanik, M. Szczepanik, K. Marcińska, W. Ptak, M. Leśkiewicz, M. Maes, A. Basta-Kaim, B. Budziszewska, J. Detka, W. Duda, W. Lasoń, Inhibitory effect of antidepressant drugs on contact hypersensitivity reaction, *Pharmacol. Rep.* 64 (2012) 714–722.
- [76] A.M. Genaro, V.A. Edgar, L. Sterin-Borda, ein-coupled receptors. 5 depending on the biochemical pathways triggered by distinct mitogens, *Biochem. Pharmacol.* 60 (2000) 1279–1283.
- [77] M.G. Frank, S.E. Hendricks, D.R. Johnson, J.L. Wieseler, W.J. Burke, Antidepressants augment natural killer cell activity: in vivo and in vitro, *Neuropsychobiology* 39 (1999) 18–24.
- [78] S.C. Dulawa, K.A. Holick, B. Gundersen, R. Hen, Effects of chronic fluoxetine in animal models of anxiety and depression, *Neuropsychopharmacology* 29 (2004) 1321–1330.
- [79] L.M. Koran, J.W. Cain, R.A. Dominguez, A.J. Rush, S. Thiemann, Are fluoxetine plasma levels related to outcome in obsessive-compulsive disorder? *Am. J. Psychiatry* 153 (1996) 1450–1454.